Please enable JavaScript to continue using this application.

Compare $CLNN vs $XLO | Chartloom

Compare

$CLNN vs $XLO

Clene Inc · Xilio Therapeutics Inc

CLNN

Clene Inc

XLO

Xilio Therapeutics Inc

Compare $CLNN vs $XLO

Comparing Clene Inc and Xilio Therapeutics Inc

CLNNClene Inc

XLOXilio Therapeutics Inc

CLNNClene Inc

Market cap

$49M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

176.51x

Rev growth (TTM)

-31.1%

YTD performance

-33.1%

52W performance

-59.0%

FCF yield

-32.3%

XLOXilio Therapeutics Inc

Market cap

$54M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

3.42x

Rev growth (TTM)

327.3%

YTD performance

-3.8%

52W performance

-23.1%

FCF yield

-113.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CLNN

XLO

Detailed metrics comparison

CLNN

Clene Inc

XLO

Xilio Therapeutics Inc

Market Cap

CLNN$49M

XLO$54M

Enterprise Value

CLNN$58M

XLO$-82M

Price

CLNN$3.86

XLO$9.05

P/E Ratio

CLNNN/A

XLON/A

P/S Ratio

CLNN250.41x

XLO0.84x

EV/Sales

CLNN296.36x

XLO-1.28x

EV/EBITDA

CLNN0.00x

XLO0.00x

P/B Ratio

CLNN13.60x

XLO0.82x

P/FCF Ratio

CLNNN/A

XLON/A

EV/FCF

CLNN-3.66x

XLO1.34x

PEG Ratio

CLNNN/A

XLON/A

Forward P/E (NTM)

CLNNN/A

XLON/A

Forward P/S (NTM)

CLNN176.51x

XLO3.42x

Revenue (TTM)

CLNN$197K

XLO$64M

Revenue Growth (YoY)

CLNN-31.1%

XLO327.3%

Forward Rev Growth

CLNN10485.4%

XLO-34.2%

Gross Margin (TTM)

CLNN70.1%

XLO0.0%

Operating Margin (TTM)

CLNN0.0%

XLO0.0%

EBITDA Margin (TTM)

CLNN-9704.6%

XLO-46.9%

Net Margin (TTM)

CLNN-20059.9%

XLO-34.1%

FCF Margin (TTM)

CLNN-8094.9%

XLO-95.6%

Net Income (TTM)

CLNN$-40M

XLO$-22M

FCF (TTM)

CLNN$-16M

XLO$-61M

EPS (TTM)

CLNN-$3.19

XLO-$1.12

ROE (TTM)

CLNN-32223.0%

XLO-923.0%

ROA (TTM)

CLNN-18564.0%

XLO-1441.0%

ROIC (TTM)

CLNN-11721.0%

XLO-923.0%

Cash

CLNN$10M

XLO$136M

Debt

CLNN$19M

XLO$0

Net Cash/Debt

CLNN$-9M

XLO$136M

Current Ratio (TTM)

CLNN3.07x

XLO4.25x

Quick Ratio (TTM)

CLNN2.91x

XLO4.15x

Debt/Equity (TTM)

CLNN6.36x

XLO0.00x

Debt/Assets (TTM)

CLNN0.0%

XLO0.0%

Interest Coverage (TTM)

CLNNN/A

XLON/A

Net Debt/EBITDA (TTM)

CLNN0.00x

XLO0.00x

Beta

CLNN1.06

XLO-0.12

52W Performance

CLNN-59.0%

XLO-23.1%

YTD Performance

CLNN-33.1%

XLO-3.8%

% from 52W High

CLNN-71.4%

XLO-28.1%

% from 52W Low

CLNN18.8%

XLO40.0%

Asset Turnover (TTM)

CLNN0.01x

XLO0.42x

FCF Yield (TTM)

CLNN-32.3%

XLO-113.2%

Earnings Yield (TTM)

CLNN-80.1%

XLO-40.3%

Dividend Yield (TTM)

CLNNN/A

XLON/A

Rule of 40

CLNN-8,126.0

XLO231.7

EV/GP/RG

CLNN10.10

XLON/A

Ticker research

View CLNN research View XLO research

Metric	CLNN Clene Inc	XLO Xilio Therapeutics Inc
Market & Valuation
Market Cap	$49M	$54M
Enterprise Value	$58M	$-82M
Price	$3.86	$9.05
P/E Ratio	N/A	N/A
P/S Ratio	250.41x	0.84x
EV/Sales	296.36x	-1.28x
EV/EBITDA	0.00x	0.00x
P/B Ratio	13.60x	0.82x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.66x	1.34x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	176.51x	3.42x
Revenue & Growth
Revenue (TTM)	$197K	$64M
Revenue Growth (YoY)	-31.1%	327.3%
Forward Rev Growth	10485.4%	-34.2%
Profitability
Gross Margin (TTM)	70.1%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-9704.6%	-46.9%
Net Margin (TTM)	-20059.9%	-34.1%
FCF Margin (TTM)	-8094.9%	-95.6%
Net Income (TTM)	$-40M	$-22M
FCF (TTM)	$-16M	$-61M
EPS (TTM)	-$3.19	-$1.12
ROE (TTM)	-32223.0%	-923.0%
ROA (TTM)	-18564.0%	-1441.0%
ROIC (TTM)	-11721.0%	-923.0%
Financial Health
Cash	$10M	$136M
Debt	$19M	$0
Net Cash/Debt	$-9M	$136M
Current Ratio (TTM)	3.07x	4.25x
Quick Ratio (TTM)	2.91x	4.15x
Debt/Equity (TTM)	6.36x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.06	-0.12
52W Performance	-59.0%	-23.1%
YTD Performance	-33.1%	-3.8%
% from 52W High	-71.4%	-28.1%
% from 52W Low	18.8%	40.0%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.42x
FCF Yield (TTM)	-32.3%	-113.2%
Earnings Yield (TTM)	-80.1%	-40.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-8,126.0	231.7
EV/GP/RG	10.10	N/A
Ticker research	View CLNN research	View XLO research

Valuation

P/S Ratio

XLO

0.84x

CLNN

250.41x

EV/FCF

CLNN

-3.66x

XLO

1.34x

Growth & revenue

Revenue Growth TTM

XLO

327.3%

CLNN

-31.1%

Forward Revenue Growth

CLNN

10485.4%

XLO

-34.2%

Profitability & performance

Gross Margin

CLNN

70.1%

XLO

0.0%

ROE

XLO

-923.0%

CLNN

-32223.0%

FCF Yield %

CLNN

-32.3%

XLO

-113.2%

52-Week Performance

XLO

-23.1%

CLNN

-59.0%

Detailed metrics comparison

CLNN

Clene Inc

XLO

Xilio Therapeutics Inc

Market Cap

CLNN$49M

XLO$54M

Enterprise Value

CLNN$58M

XLO$-82M

Price

CLNN$3.86

XLO$9.05

P/E Ratio

CLNNN/A

XLON/A

P/S Ratio

CLNN250.41x

XLO0.84x

EV/Sales

CLNN296.36x

XLO-1.28x

EV/EBITDA

CLNN0.00x

XLO0.00x

P/B Ratio

CLNN13.60x

XLO0.82x

P/FCF Ratio

CLNNN/A

XLON/A

EV/FCF

CLNN-3.66x

XLO1.34x

PEG Ratio

CLNNN/A

XLON/A

Forward P/E (NTM)

CLNNN/A

XLON/A

Forward P/S (NTM)

CLNN176.51x

XLO3.42x

Revenue (TTM)

CLNN$197K

XLO$64M

Revenue Growth (YoY)

CLNN-31.1%

XLO327.3%

Forward Rev Growth

CLNN10485.4%

XLO-34.2%

Gross Margin (TTM)

CLNN70.1%

XLO0.0%

Operating Margin (TTM)

CLNN0.0%

XLO0.0%

EBITDA Margin (TTM)

CLNN-9704.6%

XLO-46.9%

Net Margin (TTM)

CLNN-20059.9%

XLO-34.1%

FCF Margin (TTM)

CLNN-8094.9%

XLO-95.6%

Net Income (TTM)

CLNN$-40M

XLO$-22M

FCF (TTM)

CLNN$-16M

XLO$-61M

EPS (TTM)

CLNN-$3.19

XLO-$1.12

ROE (TTM)

CLNN-32223.0%

XLO-923.0%

ROA (TTM)

CLNN-18564.0%

XLO-1441.0%

ROIC (TTM)

CLNN-11721.0%

XLO-923.0%

Cash

CLNN$10M

XLO$136M

Debt

CLNN$19M

XLO$0

Net Cash/Debt

CLNN$-9M

XLO$136M

Current Ratio (TTM)

CLNN3.07x

XLO4.25x

Quick Ratio (TTM)

CLNN2.91x

XLO4.15x

Debt/Equity (TTM)

CLNN6.36x

XLO0.00x

Debt/Assets (TTM)

CLNN0.0%

XLO0.0%

Interest Coverage (TTM)

CLNNN/A

XLON/A

Net Debt/EBITDA (TTM)

CLNN0.00x

XLO0.00x

Beta

CLNN1.06

XLO-0.12

52W Performance

CLNN-59.0%

XLO-23.1%

YTD Performance

CLNN-33.1%

XLO-3.8%

% from 52W High

CLNN-71.4%

XLO-28.1%

% from 52W Low

CLNN18.8%

XLO40.0%

Asset Turnover (TTM)

CLNN0.01x

XLO0.42x

FCF Yield (TTM)

CLNN-32.3%

XLO-113.2%

Earnings Yield (TTM)

CLNN-80.1%

XLO-40.3%

Dividend Yield (TTM)

CLNNN/A

XLON/A

Rule of 40

CLNN-8,126.0

XLO231.7

EV/GP/RG

CLNN10.10

XLON/A

Ticker research

View CLNN research View XLO research

Metric	CLNN Clene Inc	XLO Xilio Therapeutics Inc
Market & Valuation
Market Cap	$49M	$54M
Enterprise Value	$58M	$-82M
Price	$3.86	$9.05
P/E Ratio	N/A	N/A
P/S Ratio	250.41x	0.84x
EV/Sales	296.36x	-1.28x
EV/EBITDA	0.00x	0.00x
P/B Ratio	13.60x	0.82x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.66x	1.34x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	176.51x	3.42x
Revenue & Growth
Revenue (TTM)	$197K	$64M
Revenue Growth (YoY)	-31.1%	327.3%
Forward Rev Growth	10485.4%	-34.2%
Profitability
Gross Margin (TTM)	70.1%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-9704.6%	-46.9%
Net Margin (TTM)	-20059.9%	-34.1%
FCF Margin (TTM)	-8094.9%	-95.6%
Net Income (TTM)	$-40M	$-22M
FCF (TTM)	$-16M	$-61M
EPS (TTM)	-$3.19	-$1.12
ROE (TTM)	-32223.0%	-923.0%
ROA (TTM)	-18564.0%	-1441.0%
ROIC (TTM)	-11721.0%	-923.0%
Financial Health
Cash	$10M	$136M
Debt	$19M	$0
Net Cash/Debt	$-9M	$136M
Current Ratio (TTM)	3.07x	4.25x
Quick Ratio (TTM)	2.91x	4.15x
Debt/Equity (TTM)	6.36x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.06	-0.12
52W Performance	-59.0%	-23.1%
YTD Performance	-33.1%	-3.8%
% from 52W High	-71.4%	-28.1%
% from 52W Low	18.8%	40.0%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.42x
FCF Yield (TTM)	-32.3%	-113.2%
Earnings Yield (TTM)	-80.1%	-40.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-8,126.0	231.7
EV/GP/RG	10.10	N/A
Ticker research	View CLNN research	View XLO research